Search

Non-Alcoholic Fatty Liver Disease (NAFLD) is a common condition affecting around 10–25% of the general adult population, 15% of children, and even > 50% of individuals who have type 2 diabetes mellitus. It is a major cause of liver-related morbidity, and cardiovascular (CV) mortality is a common cause of death. In addition to being the initial step of irreversible alterations of the liver parenchyma causing cirrhosis, about 1/6 of those who develop NASH are at risk also developing CV disease (CVD). More recently the acronym MAFLD (Metabolic Associated Fatty Liver Disease) has been preferred by many European and US specialists, providing a clearer message on the metabolic etiology of the disease.The suggestions for the management of NAFLD are like those recommended by guidelines for CVD prevention. In this context, the general approach is to prescribe physical activity and dietary changes the effect weight loss. Lifestyle change in the NAFLD patient has been supplemented in some by the use of nutraceuticals, but the evidence based for these remains uncertain. The aim of this Position Paper was to summarize the clinical evidence relating to the effect of nutraceuticals on NAFLD-related parameters. Our reading of the data is that whilst many nutraceuticals have been studied in relation to NAFLD, none have sufficient evidence to recommend their routine use; robust trials are required to appropriately address efficacy and safety.

Background: The recently published COMPLETE trial has demonstrated that patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD), who underwent successful percutaneous coronary intervention (PCI) of both culprit and non-culprit (vs. culprit-only) lesions had a reduced risk of major adverse cardiac events (MACE), but not of cardiovascular or total mortality. The aim of this meta-analysis was to assess the efficacy of complete revascularization on cardiovascular or total mortality reduction using available randomized controlled trials (RCTs) including the COMPLETE trial, in hemodynamically stable STEMI patients with MVD. Methods: PubMed, MEDLINE, Embase, Scopus, Google Scholar, CENTRAL and ClinicalTrials.gov databases search identified 10 RCTs of 7033 patients with STEMI and MVD which compared complete (n = 3420) vs. only culprit lesion (n = 3613) PCI for a median 27.7 months follow-up. Random effect risk ratios were used to estimate for efficacy and safety outcomes. Results: Complete revascularization reduced the risk of MACE (10.4% vs.16.6%; RR = 0.59, 95% CI: 0.47 to 0.74, p

Objective: We aimed in this study to assess the role of longitudinal left ventricular (LV) systolic function in heart failure with preserved ejection fraction (HFpEF) in delayed intra- and interatrial conduction time. Methods: In 85 consecutive patients with HFpEF (age 60±11 years, ejection fraction [EF] ≥45%), a complete M-mode echocardiographic and tissue Doppler imaging (TDI) study was performed. The times from the onset of the P wave on the ECG to the beginning of the A′ wave (PA) from the lateral and septal mitral and tricuspid annuli on TDI were recorded. The difference between these intervals gave the intra- and interatrial dyssynchrony. Based on mitral annular plane systolic excursion (MAPSE), patients were classified as having HFpEF with impaired (MAPSE ≤1.2 cm) or normal (MAPSE >1.2 cm) longitudinal systolic function. Results: Patients with impaired MAPSE were older (p 1,2 cm). Resultados: Os doentes com ESPAM baixa eram mais velhos (p < 0,001), tinham índice de massa VE mais elevado (p < 0,001), volume auricular esquerdo (VAE) superior (p = 0,007), FE auricular esquerda (AE) mais baixa (p < 0,001), rácio E/e’ mais elevado (p = 0,002), onda e’ lateral e septal reduzidas (p = 0,005 e p = 0,006), onda tricúspide PA prolongada (p = 0,03) e aumento significativo da dessincronia da aurícula direita (AD) (p = 0,001), quando comparados com doentes com ESPAM normal. A ESPAM estava correlacionada com a dessincronia AD (r = -0,40, p < 0,001), mas não com a dessincronia interauricular e da AE. Conclusão: Nos doentes com ICFEp e ESPAM baixa, existe dessincronia AD, quando comparada com os doentes com ESPAM normal. Como os doentes com dessincronia AD têm risco mais elevado de arritmia, a avaliação desta dessincronia pode ajudar a melhorar o tratamento, bem como a auxiliar na previsão prognóstica destes doentes. Keywords: Heart failure, Right atrial dyssynchrony, Systolic longitudinal function, Palavras-chave: Insuficiência cardíaca, Dessincronia auricular direita, Função sistólica longitudinal